▟ Vinebot intrinsic value, daily

← back

COR Cencora

healthcare · valued with opus medium conviction · deep-dived 2026-10-16

HOLD
Intrinsic value$151.01
Price (at call)$341.41
Margin of safety -55.8%
vs market (rating basis) -16.0%

Oligopoly toll collector on US drug spend; fairly priced if specialty mix lifts margins to about 1.3%.

The story

Cencora is one of three US drug wholesalers that together control over 90% of the market. The oligopoly has scale and regulatory moats, and it earns thin but very stable margins on huge volumes. Specialty distribution (oncology and physician practices), GLP-1 pass-through volume, and services businesses like animal health and biopharma consulting drive growth. It is a mature, cash-generative compounder with high returns on capital, not a high-growth story.

Specialty drugs and GLP-1s keep top-line growth high, near the 10% five-year CAGR, before it fades to inflation-like 3%. Margin rises modestly from about 0.8% reported (1.2% TTM) to 1.3% as specialty mix and services offset low-margin GLP-1 volume, which is still below peak-adjusted levels. Sales-to-capital is set at 20 rather than the observed 36 to allow for working-capital needs and tuck-in M&A. The baseline DCF's 0.8% margin cannot reconcile with a $65B market cap; at about 1.3% and roughly 9% growth, the gap closes to a plausible range.

Value drivers

Revenue growth (Y1)9.0%
Terminal growth3.0%
Forecast horizon8y
Target operating margin1.3%
Years to target margin4
Sales-to-capital6.00
Beta0.80
Failure probability2.0%
Cost of capital (WACC)8.3%
Terminal WACC9.1%

Valuation bridge

PV of explicit FCFF-1.54B
PV of terminal value34.48B
Equity value28.82B
÷ shares → per share$151.01

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 362.72B 9.0% 1.3% 3.16B 4.99B -1.84B -1.70B
2 392.26B 8.1% 1.3% 3.46B 4.92B -1.47B -1.25B
3 420.84B 7.3% 1.3% 3.75B 4.76B -1.01B -796.64M
4 447.89B 6.4% 1.3% 4.04B 4.51B -466.73M -339.83M
5 472.84B 5.6% 1.3% 4.27B 4.16B 108.46M 72.95M
6 495.13B 4.7% 1.3% 4.47B 3.72B 753.41M 468.08M
7 514.23B 3.9% 1.3% 4.64B 3.18B 1.46B 836.72M
8 529.66B 3.0% 1.3% 4.78B 2.57B 2.21B 1.17B

Key risks

  • GLP-1 and branded pass-through volume inflates revenue but dilutes margin, and manufacturer fee renegotiation could squeeze spreads
  • Drug pricing policy (IRA negotiation, PBM reform, tariffs) compresses wholesale economics or reroutes distribution
  • Customer concentration with Walgreens, plus residual opioid litigation and settlement cash outflows

Catalysts

  • Continued specialty and oncology share gains plus the MSO/physician services rollups (RCA, OneOncology) lifting mix
  • Biosimilar adoption, which carries higher distributor margins than branded drugs

History

DatePriceIntrinsicMoSRating
2026-10-16$341.41 $151.01 -55.8% HOLD
2026-08-27$327.79 $130.45 -60.2% HOLD
2026-07-07$298.55 $316.05 +5.9% STRONG BUY
2026-06-23$281.10 $319.54 +13.7% STRONG BUY